Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis
Studies comparing rabbit antithymocyte globulin (rATG) and horse ATG (hATG) in patients with aplastic anemia (AA) have shown conflicting results. These studies included fewer than 60 subjects in the rATG arm with relatively short follow-up. A total of 169 patients treated with rATG and 62 treated wi...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2015-06, Vol.94 (6), p.947-954 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 954 |
|---|---|
| container_issue | 6 |
| container_start_page | 947 |
| container_title | Annals of hematology |
| container_volume | 94 |
| creator | Vallejo, Carlos Montesinos, Pau Polo, Marta Cuevas, Beatriz Morado, Marta Rosell, Ana Xicoy, Blanca Díez, José L. Salamero, Olga Cedillo, Ángel Martínez, Pablo Rayón, Consolación |
| description | Studies comparing rabbit antithymocyte globulin (rATG) and horse ATG (hATG) in patients with aplastic anemia (AA) have shown conflicting results. These studies included fewer than 60 subjects in the rATG arm with relatively short follow-up. A total of 169 patients treated with rATG and 62 treated with hATG were included in this retrospective analysis, across 33 centers. Patients were treated with rATG or hATG plus cyclosporine A. Over half were classified, as having severe AA (SAA) or very severe AA (VSAA), and the mean follow-up was 45 months. There was no significant difference detected in cumulative response to treatment or survival between the rATG and hATG groups. The response to treatment was 63 % in the rATG group versus 66 % in the hATG group at 3 months. By 12 months, this pattern had reversed, and 84 % of rATG patients had responded to treatment versus 76 % in the hATG group (n.s.). Early mortality due to infection tended to be higher with rATG compared to hATG (n.s). rATG and hATG would seem to be therapeutically equivalent in SAA and VSAA. However, patients treated with rATG may take longer to respond than those treated with hATG and may also require more active prevention of early infections. |
| doi_str_mv | 10.1007/s00277-015-2305-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1680189084</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3759857371</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-daa2b96faa2280f19e1c0e05ff5df5c061feae67f945336bdf08929bc28810313</originalsourceid><addsrcrecordid>eNp1kcFKHTEUhkNpqVftA7gpgW66mfYkmcwk3RWxKgiFUtchkznRyMzNNckI9wF87-Z6rZSC2ZxFvv_PCR8hJwy-MID-awbgfd8Akw0XIBvxhqxYK3gDUrVvyQq00I2s54Ac5nwHwLhq-XtywGXX867VK_L4yw5DKNSuSyi32zm6bUF6M8VhmcKaPmDKS6a3MWV8jfEx0ZLQlhnXhUZPrbtfQsKR2s1kcwmuJnEO9hu1NGFJMW_QlfCwa7TTNod8TN55O2X88DyPyPWPs9-nF83Vz_PL0-9XjZOgSjNaywfd-Tq4As80MgcI0ns5eumgYx4tdr3XrRSiG0YPSnM9OK4UA8HEEfm8792keL9gLmYO2eE01QXjkg3rFDClQbUV_fQfeheXVPfdUVpzYPqpkO0pV3-VE3qzSWG2aWsYmJ0js3dkqiOzc2REzXx8bl6GGceXxF8pFeB7INer9Q2mf55-tfUPCZWfgw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1699201931</pqid></control><display><type>article</type><title>Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Vallejo, Carlos ; Montesinos, Pau ; Polo, Marta ; Cuevas, Beatriz ; Morado, Marta ; Rosell, Ana ; Xicoy, Blanca ; Díez, José L. ; Salamero, Olga ; Cedillo, Ángel ; Martínez, Pablo ; Rayón, Consolación</creator><creatorcontrib>Vallejo, Carlos ; Montesinos, Pau ; Polo, Marta ; Cuevas, Beatriz ; Morado, Marta ; Rosell, Ana ; Xicoy, Blanca ; Díez, José L. ; Salamero, Olga ; Cedillo, Ángel ; Martínez, Pablo ; Rayón, Consolación ; Bone Marrow Failure Spanish Study Group (Pethema-GETH) ; The Bone Marrow Failure Spanish Study Group (Pethema-GETH)</creatorcontrib><description>Studies comparing rabbit antithymocyte globulin (rATG) and horse ATG (hATG) in patients with aplastic anemia (AA) have shown conflicting results. These studies included fewer than 60 subjects in the rATG arm with relatively short follow-up. A total of 169 patients treated with rATG and 62 treated with hATG were included in this retrospective analysis, across 33 centers. Patients were treated with rATG or hATG plus cyclosporine A. Over half were classified, as having severe AA (SAA) or very severe AA (VSAA), and the mean follow-up was 45 months. There was no significant difference detected in cumulative response to treatment or survival between the rATG and hATG groups. The response to treatment was 63 % in the rATG group versus 66 % in the hATG group at 3 months. By 12 months, this pattern had reversed, and 84 % of rATG patients had responded to treatment versus 76 % in the hATG group (n.s.). Early mortality due to infection tended to be higher with rATG compared to hATG (n.s). rATG and hATG would seem to be therapeutically equivalent in SAA and VSAA. However, patients treated with rATG may take longer to respond than those treated with hATG and may also require more active prevention of early infections.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-015-2305-3</identifier><identifier>PMID: 25672649</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Anemia, Aplastic - blood ; Anemia, Aplastic - diagnosis ; Anemia, Aplastic - drug therapy ; Animals ; Antilymphocyte Serum - administration & dosage ; Female ; Follow-Up Studies ; Hematology ; Horses ; Humans ; Infusions, Intravenous ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Rabbits ; Retrospective Studies ; Species Specificity ; Treatment Outcome ; Young Adult</subject><ispartof>Annals of hematology, 2015-06, Vol.94 (6), p.947-954</ispartof><rights>Springer-Verlag Berlin Heidelberg 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-daa2b96faa2280f19e1c0e05ff5df5c061feae67f945336bdf08929bc28810313</citedby><cites>FETCH-LOGICAL-c508t-daa2b96faa2280f19e1c0e05ff5df5c061feae67f945336bdf08929bc28810313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-015-2305-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-015-2305-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25672649$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vallejo, Carlos</creatorcontrib><creatorcontrib>Montesinos, Pau</creatorcontrib><creatorcontrib>Polo, Marta</creatorcontrib><creatorcontrib>Cuevas, Beatriz</creatorcontrib><creatorcontrib>Morado, Marta</creatorcontrib><creatorcontrib>Rosell, Ana</creatorcontrib><creatorcontrib>Xicoy, Blanca</creatorcontrib><creatorcontrib>Díez, José L.</creatorcontrib><creatorcontrib>Salamero, Olga</creatorcontrib><creatorcontrib>Cedillo, Ángel</creatorcontrib><creatorcontrib>Martínez, Pablo</creatorcontrib><creatorcontrib>Rayón, Consolación</creatorcontrib><creatorcontrib>Bone Marrow Failure Spanish Study Group (Pethema-GETH)</creatorcontrib><creatorcontrib>The Bone Marrow Failure Spanish Study Group (Pethema-GETH)</creatorcontrib><title>Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Studies comparing rabbit antithymocyte globulin (rATG) and horse ATG (hATG) in patients with aplastic anemia (AA) have shown conflicting results. These studies included fewer than 60 subjects in the rATG arm with relatively short follow-up. A total of 169 patients treated with rATG and 62 treated with hATG were included in this retrospective analysis, across 33 centers. Patients were treated with rATG or hATG plus cyclosporine A. Over half were classified, as having severe AA (SAA) or very severe AA (VSAA), and the mean follow-up was 45 months. There was no significant difference detected in cumulative response to treatment or survival between the rATG and hATG groups. The response to treatment was 63 % in the rATG group versus 66 % in the hATG group at 3 months. By 12 months, this pattern had reversed, and 84 % of rATG patients had responded to treatment versus 76 % in the hATG group (n.s.). Early mortality due to infection tended to be higher with rATG compared to hATG (n.s). rATG and hATG would seem to be therapeutically equivalent in SAA and VSAA. However, patients treated with rATG may take longer to respond than those treated with hATG and may also require more active prevention of early infections.</description><subject>Adult</subject><subject>Aged</subject><subject>Anemia, Aplastic - blood</subject><subject>Anemia, Aplastic - diagnosis</subject><subject>Anemia, Aplastic - drug therapy</subject><subject>Animals</subject><subject>Antilymphocyte Serum - administration & dosage</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology</subject><subject>Horses</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Rabbits</subject><subject>Retrospective Studies</subject><subject>Species Specificity</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kcFKHTEUhkNpqVftA7gpgW66mfYkmcwk3RWxKgiFUtchkznRyMzNNckI9wF87-Z6rZSC2ZxFvv_PCR8hJwy-MID-awbgfd8Akw0XIBvxhqxYK3gDUrVvyQq00I2s54Ac5nwHwLhq-XtywGXX867VK_L4yw5DKNSuSyi32zm6bUF6M8VhmcKaPmDKS6a3MWV8jfEx0ZLQlhnXhUZPrbtfQsKR2s1kcwmuJnEO9hu1NGFJMW_QlfCwa7TTNod8TN55O2X88DyPyPWPs9-nF83Vz_PL0-9XjZOgSjNaywfd-Tq4As80MgcI0ns5eumgYx4tdr3XrRSiG0YPSnM9OK4UA8HEEfm8792keL9gLmYO2eE01QXjkg3rFDClQbUV_fQfeheXVPfdUVpzYPqpkO0pV3-VE3qzSWG2aWsYmJ0js3dkqiOzc2REzXx8bl6GGceXxF8pFeB7INer9Q2mf55-tfUPCZWfgw</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Vallejo, Carlos</creator><creator>Montesinos, Pau</creator><creator>Polo, Marta</creator><creator>Cuevas, Beatriz</creator><creator>Morado, Marta</creator><creator>Rosell, Ana</creator><creator>Xicoy, Blanca</creator><creator>Díez, José L.</creator><creator>Salamero, Olga</creator><creator>Cedillo, Ángel</creator><creator>Martínez, Pablo</creator><creator>Rayón, Consolación</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150601</creationdate><title>Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis</title><author>Vallejo, Carlos ; Montesinos, Pau ; Polo, Marta ; Cuevas, Beatriz ; Morado, Marta ; Rosell, Ana ; Xicoy, Blanca ; Díez, José L. ; Salamero, Olga ; Cedillo, Ángel ; Martínez, Pablo ; Rayón, Consolación</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-daa2b96faa2280f19e1c0e05ff5df5c061feae67f945336bdf08929bc28810313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anemia, Aplastic - blood</topic><topic>Anemia, Aplastic - diagnosis</topic><topic>Anemia, Aplastic - drug therapy</topic><topic>Animals</topic><topic>Antilymphocyte Serum - administration & dosage</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology</topic><topic>Horses</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Rabbits</topic><topic>Retrospective Studies</topic><topic>Species Specificity</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vallejo, Carlos</creatorcontrib><creatorcontrib>Montesinos, Pau</creatorcontrib><creatorcontrib>Polo, Marta</creatorcontrib><creatorcontrib>Cuevas, Beatriz</creatorcontrib><creatorcontrib>Morado, Marta</creatorcontrib><creatorcontrib>Rosell, Ana</creatorcontrib><creatorcontrib>Xicoy, Blanca</creatorcontrib><creatorcontrib>Díez, José L.</creatorcontrib><creatorcontrib>Salamero, Olga</creatorcontrib><creatorcontrib>Cedillo, Ángel</creatorcontrib><creatorcontrib>Martínez, Pablo</creatorcontrib><creatorcontrib>Rayón, Consolación</creatorcontrib><creatorcontrib>Bone Marrow Failure Spanish Study Group (Pethema-GETH)</creatorcontrib><creatorcontrib>The Bone Marrow Failure Spanish Study Group (Pethema-GETH)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vallejo, Carlos</au><au>Montesinos, Pau</au><au>Polo, Marta</au><au>Cuevas, Beatriz</au><au>Morado, Marta</au><au>Rosell, Ana</au><au>Xicoy, Blanca</au><au>Díez, José L.</au><au>Salamero, Olga</au><au>Cedillo, Ángel</au><au>Martínez, Pablo</au><au>Rayón, Consolación</au><aucorp>Bone Marrow Failure Spanish Study Group (Pethema-GETH)</aucorp><aucorp>The Bone Marrow Failure Spanish Study Group (Pethema-GETH)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>94</volume><issue>6</issue><spage>947</spage><epage>954</epage><pages>947-954</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Studies comparing rabbit antithymocyte globulin (rATG) and horse ATG (hATG) in patients with aplastic anemia (AA) have shown conflicting results. These studies included fewer than 60 subjects in the rATG arm with relatively short follow-up. A total of 169 patients treated with rATG and 62 treated with hATG were included in this retrospective analysis, across 33 centers. Patients were treated with rATG or hATG plus cyclosporine A. Over half were classified, as having severe AA (SAA) or very severe AA (VSAA), and the mean follow-up was 45 months. There was no significant difference detected in cumulative response to treatment or survival between the rATG and hATG groups. The response to treatment was 63 % in the rATG group versus 66 % in the hATG group at 3 months. By 12 months, this pattern had reversed, and 84 % of rATG patients had responded to treatment versus 76 % in the hATG group (n.s.). Early mortality due to infection tended to be higher with rATG compared to hATG (n.s). rATG and hATG would seem to be therapeutically equivalent in SAA and VSAA. However, patients treated with rATG may take longer to respond than those treated with hATG and may also require more active prevention of early infections.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25672649</pmid><doi>10.1007/s00277-015-2305-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2015-06, Vol.94 (6), p.947-954 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1680189084 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Anemia, Aplastic - blood Anemia, Aplastic - diagnosis Anemia, Aplastic - drug therapy Animals Antilymphocyte Serum - administration & dosage Female Follow-Up Studies Hematology Horses Humans Infusions, Intravenous Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Rabbits Retrospective Studies Species Specificity Treatment Outcome Young Adult |
| title | Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T19%3A15%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rabbit%20antithymocyte%20globulin%20versus%20horse%20antithymocyte%20globulin%20for%20treatment%20of%20acquired%20aplastic%20anemia:%20a%20retrospective%20analysis&rft.jtitle=Annals%20of%20hematology&rft.au=Vallejo,%20Carlos&rft.aucorp=Bone%20Marrow%20Failure%20Spanish%20Study%20Group%20(Pethema-GETH)&rft.date=2015-06-01&rft.volume=94&rft.issue=6&rft.spage=947&rft.epage=954&rft.pages=947-954&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-015-2305-3&rft_dat=%3Cproquest_cross%3E3759857371%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1699201931&rft_id=info:pmid/25672649&rfr_iscdi=true |